{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Thoroughly Thriving","title":"AI Won't Replace Drug Discovery—Here's What It Will Do with Kevin Krause | #36","html":"","width":"100%","height":180,"duration":2168,"description":"What is AI actually changing in drug discovery—and what's simply hype?\n\nIn Episode 36 of Thoroughly Thriving, Darren and Sean sit down with Kevin Krause, President and CEO of ArrePath, for a practical conversation about biotech leadership, AI/ML-driven drug discovery, strategic decision-making, and building companies differently.\nKevin has spent more than two decades working at the intersection of science and strategy. His career has taken him from the research bench into clinical development, corporate development, commercial strategy and ultimately the CEO chair. Along the way, he contributed to seven approved antibiotics and gained a rare view of what it actually takes to move a medicine from discovery toward patients.\nToday, Kevin is leading ArrePath as it applies AI and machine learning to drug discovery.\nBut his perspective is refreshingly straightforward:\nAI isn't the product. The medicine is.\n\nKevin explains how machine learning can help scientists explore chemistry faster, predict multiple drug-development parameters simultaneously, reduce costs, increase creativity, and compress work that once required weeks into hours.\n\nWe discuss:\nKevin's unconventional path from scientist to CEO\nWhy strategic thinking changed his career\nA practical framework for making better decisions\nWhat seven drug approvals taught him about biotech strategy\nWhy good drugs can still miss their market opportunity\nThe importance of listening to regulators and external advisors\nHow ArrePath is expanding beyond infectious disease\nHow six people can manage multiple active research programs\nWhat AI/ML drug discovery actually looks like day-to-day\nWhy AI should augment scientists rather than replace them\nUsing machine learning to predict oral bioavailability and other properties\nHow agentic AI can accelerate research and decision-making\nWhy biotech companies need to stop simply saying \"we use AI\"\nHow leaders can prove AI's value to boards, partners and investors\nWhether you're working in...","thumbnail_url":"https://img.transistorcdn.com/kbajRkWd2zskg-dDekq9u_0PcI2XS8Pshh684sR6p20/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9jZGQ3/NTUzNTBlOTNlODZm/MDgxNTg0MDMzZjBl/MmU4Yy5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}